Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
FAQs
Advertise
UsernamePublicRestriction
Tags:
BioPharmaceutical Clinical Trials Research and Development Strategies

Astellas' Phase III Front-Line AML Study Of Xospata Fails

Standard Of Care Has Shifted Since Trial's Initiation

  • News

Executive Summary

One expert said the company should focus efforts on developing the drug for maintenance treatment of AML.

You may also be interested in...



Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track: FDA OKs AMAG's Vyleesi, But Bronchitol And Quizartinib Draw CRLs

The latest drug development news and highlights from our US FDA Performance Tracker.

Roche’s Actemra Scores New Indication In Rare Autoimmune Disease

The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Clinical Trials Research and Development Strategies
UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By